

Randomized Phase

OLE Phase

≤40 months

**July 2020**

Original survival assessment

Updated dataset from original publication that includes 1 additional participant whose vital status was ascertained since original assessment

**March 2021**

Final survival assessment

Analysis includes a more mature dataset. As such, the number of individuals at risk at each timepoint may increase as more participants reach that timing milestone

## Survival Analyses (Time To All-Cause Death)

Analysis	Population(s)	Comparators
ITT	ITT <sup>a</sup>	<ul style="list-style-type: none"> <li>Group originally randomized to PB and TURSO vs group originally randomized to placebo</li> </ul>
RPSFTM	<ul style="list-style-type: none"> <li>ITT<sup>a</sup></li> <li>RPSFTM Adjusted</li> </ul>	<ul style="list-style-type: none"> <li>Group originally randomized to PB and TURSO (ITT) vs group originally randomized to placebo (RPSFTM adjusted)</li> </ul>
Subgroup analysis	ITT <sup>a</sup>	<ul style="list-style-type: none"> <li>Subgroup originally randomized to PB and TURSO that entered the OLE phase vs:               <ul style="list-style-type: none"> <li>Subgroup originally randomized to placebo that entered the OLE phase</li> <li>Subgroup originally randomized to PB and TURSO that did not enter the OLE phase</li> <li>Subgroup originally randomized to placebo that did not enter the OLE phase</li> </ul> </li> </ul>